The global Cardiometabolic Drugs Market size reached USD 50 Billion in 2021. The sales of cardiometabolic drugs are estimated to surpass a valuation of USD 70 Billion by 2032, rising at a CAGR of 4% to 5% during the forecast period 2022 to 2032.
Driven by the rising emphasis on the development of novel drugs that offers better results with minimal side effects, the demand for cardiometabolic drugs is projected to top USD 55 Billion by 2022.
| Report Attribute | Details |
|---|---|
| Cardiometabolic Drugs Market Base Year Value (2021) | USD 50 Billion |
| Cardiometabolic Drugs Market Expected Value (2022) | USD 55 Billion |
| Cardiometabolic Drugs Market Anticipated Value (2032) | USD 70 Billion |
| Cardiometabolic Drugs Market Projected Growth Rate (2022 to 2032) | 4% to 5% CAGR |
Cardiometabolic drugs are therapeutics medications purposefully used for a vast composition of metabolic disorders and dysfunction including cardiovascular diseases, obesity, diabetes, hypertension, dyslipidemia, central adiposity, and others.
Due to increasing fast-paced lifestyles, changing eating habits, and rising stress levels, a substantial rise in the burden of lifestyle diseases such as diabetes, obesity, hypertension, and others is being witnessed, creating demand for treatment drugs.
For instance, according to the International Diabetic Foundation, nearly 537 million adults between the age of 20 to 79 are living with diabetes across the world and the number is estimated to reach 643 million by 2030.
As cardiometabolic disorders are extensively used by diabetic patients for diverse applications, such as insulin resistance, growing diabetic population is projected to create high remunerative opportunities in the global market.
There are number of side effects associated with the consumption of cardiometabolic drugs such as antidiabetics, anticoagulants, hypertension, dyslipidemia drug, and others such as dyspepsia, vomiting, nausea, prolonged nosebleeds, passing of blood in urine, and others. Hence, rising awareness regarding such severe adverse effects on health is hindering the sales of cardiometabolic drugs in the market.
As per Future Market Insights, North America is forecast to account for the lion’s share in the global cardiometabolic drugs market between 2022 and 2032.
Cardiometabolic disorders and conditions involve a group of abnormalities that are interrelated, leading to a diverse constellation of cardiometabolic drugs used for each indication to limit the disease effect.
The prevalence of cardiovascular diseases is rising at a rapid pace across North America, due to the increasing pollution, smoking, opioid use, and others. According to the Centers for Disease Control and Prevention, nearly 18.2 million adults or around 6.7% of the population across the USA have coronary heart disease.
As cardiometabolic drugs play a crucial role in limiting the effect of these diseases along with their treatments, increasing burden of cardiovascular diseases is estimated to bolster the sales in the North America market.
FMI reveals that South Asia is anticipated to emerge as a highly lucrative market for cardiometabolic drugs during the forecast period 2022 to 2032.
With growing trend of personalized medication and rising demand for more effective drugs with minimal to no side effects, key manufacturers are focusing on research and development activities for the development of novel drugs.
For instance, in 2020, Natco Pharma, an Indian multinational pharmaceutical company announced launching a novel anti-blood clot medication, Rivaroxaban, under the brand name Xarelto. A multiplicity of such new product launches are expected to favor the demand for cardiometabolic drugs in the South Asia market.
Some of the leading players in the cardiometabolic drugs market are AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others.
Attributed to the presence of such high number of participants and increasing emphasis on the development and launch of for novel drugs, the market is highly competitive.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4% to 5% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Indication Type, Distribution Channel, Region |
| Countries Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa |
| Key Companies Profiled | Novartis; GlaxoSmithKline Plc.; Merck & Co., Inc.; Pfizer Inc; Bayer HealthCare Pharmaceuticals Inc.; Par Pharmaceutical; Romark Laboratories, L.C.; Lupin Pharma; Schering Corporation; Others |
| Customization | Available Upon Request |
Table 1: Global Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Cardiometabolic Drugs Market (Tons) Forecast by Region, 2017-2032
Table 3: Global Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 4: Global Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 5: Global Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 6: Global Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 7: Global Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 8: Global Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 9: Global Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 10: Global Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Table 11: North America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 12: North America Cardiometabolic Drugs Market (Tons) Forecast by Country, 2017-2032
Table 13: North America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 14: North America Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 15: North America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 16: North America Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 17: North America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 18: North America Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 19: North America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 20: North America Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Table 21: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: Latin America Cardiometabolic Drugs Market (Tons) Forecast by Country, 2017-2032
Table 23: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 24: Latin America Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 25: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 26: Latin America Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 27: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 28: Latin America Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 29: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 30: Latin America Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Table 31: Europe Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 32: Europe Cardiometabolic Drugs Market (Tons) Forecast by Country, 2017-2032
Table 33: Europe Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 34: Europe Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 35: Europe Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 36: Europe Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 37: Europe Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 38: Europe Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 39: Europe Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 40: Europe Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Table 41: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 42: East Asia Cardiometabolic Drugs Market (Tons) Forecast by Country, 2017-2032
Table 43: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 44: East Asia Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 45: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 46: East Asia Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 47: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 48: East Asia Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 49: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 50: East Asia Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Table 51: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 52: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Forecast by Country, 2017-2032
Table 53: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 54: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 55: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 56: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 57: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 58: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 59: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 60: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Table 61: MEA Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 62: MEA Cardiometabolic Drugs Market (Tons) Forecast by Country, 2017-2032
Table 63: MEA Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032
Table 64: MEA Cardiometabolic Drugs Market (Tons) Forecast by Drug Class, 2017-2032
Table 65: MEA Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Route of Administration, 2017-2032
Table 66: MEA Cardiometabolic Drugs Market (Tons) Forecast by Route of Administration, 2017-2032
Table 67: MEA Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Indication, 2017-2032
Table 68: MEA Cardiometabolic Drugs Market (Tons) Forecast by Indication, 2017-2032
Table 69: MEA Cardiometabolic Drugs Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
Table 70: MEA Cardiometabolic Drugs Market (Tons) Forecast by Distribution Channel, 2017-2032
Figure 1: Global Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 2: Global Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 3: Global Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 4: Global Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 5: Global Cardiometabolic Drugs Market Value (US$ Mn) by Region, 2022-2032
Figure 6: Global Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 7: Global Cardiometabolic Drugs Market (Tons) Analysis by Region, 2017-2032
Figure 8: Global Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 9: Global Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 10: Global Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 11: Global Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 12: Global Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 13: Global Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 14: Global Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 15: Global Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 16: Global Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 17: Global Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 18: Global Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 19: Global Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 20: Global Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 21: Global Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 22: Global Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 23: Global Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 24: Global Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 25: Global Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 26: Global Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 27: Global Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 28: Global Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 29: Global Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 30: Global Cardiometabolic Drugs Market Attractiveness by Region, 2022-2032
Figure 31: North America Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 32: North America Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 33: North America Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 34: North America Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 35: North America Cardiometabolic Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 36: North America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 37: North America Cardiometabolic Drugs Market (Tons) Analysis by Country, 2017-2032
Figure 38: North America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 39: North America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 40: North America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 41: North America Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 42: North America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 43: North America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 44: North America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 45: North America Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 46: North America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 47: North America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 48: North America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 49: North America Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 50: North America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 51: North America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 52: North America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 53: North America Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 54: North America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 55: North America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 56: North America Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 57: North America Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 58: North America Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 59: North America Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 60: North America Cardiometabolic Drugs Market Attractiveness by Country, 2022-2032
Figure 61: Latin America Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 62: Latin America Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 63: Latin America Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 64: Latin America Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 65: Latin America Cardiometabolic Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 66: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 67: Latin America Cardiometabolic Drugs Market (Tons) Analysis by Country, 2017-2032
Figure 68: Latin America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 69: Latin America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 70: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 71: Latin America Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 72: Latin America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 73: Latin America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 74: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 75: Latin America Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 76: Latin America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 77: Latin America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 78: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 79: Latin America Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 80: Latin America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 81: Latin America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 82: Latin America Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 83: Latin America Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 84: Latin America Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 85: Latin America Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 86: Latin America Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 87: Latin America Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 88: Latin America Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 89: Latin America Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 90: Latin America Cardiometabolic Drugs Market Attractiveness by Country, 2022-2032
Figure 91: Europe Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 92: Europe Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 93: Europe Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 94: Europe Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 95: Europe Cardiometabolic Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 96: Europe Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 97: Europe Cardiometabolic Drugs Market (Tons) Analysis by Country, 2017-2032
Figure 98: Europe Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 99: Europe Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 100: Europe Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 101: Europe Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 102: Europe Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 103: Europe Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 104: Europe Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 105: Europe Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 106: Europe Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 107: Europe Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 108: Europe Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 109: Europe Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 110: Europe Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 111: Europe Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 112: Europe Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 113: Europe Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 114: Europe Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 115: Europe Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 116: Europe Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 117: Europe Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 118: Europe Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 119: Europe Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 120: Europe Cardiometabolic Drugs Market Attractiveness by Country, 2022-2032
Figure 121: East Asia Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 122: East Asia Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 123: East Asia Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 124: East Asia Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 125: East Asia Cardiometabolic Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 126: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 127: East Asia Cardiometabolic Drugs Market (Tons) Analysis by Country, 2017-2032
Figure 128: East Asia Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 129: East Asia Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 130: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 131: East Asia Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 132: East Asia Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 133: East Asia Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 134: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 135: East Asia Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 136: East Asia Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 137: East Asia Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 138: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 139: East Asia Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 140: East Asia Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 141: East Asia Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 142: East Asia Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 143: East Asia Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 144: East Asia Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 145: East Asia Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 146: East Asia Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 147: East Asia Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 148: East Asia Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 149: East Asia Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 150: East Asia Cardiometabolic Drugs Market Attractiveness by Country, 2022-2032
Figure 151: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 152: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 153: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 154: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 155: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 156: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 157: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Analysis by Country, 2017-2032
Figure 158: South Asia & Pacific Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 159: South Asia & Pacific Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 160: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 161: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 162: South Asia & Pacific Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 163: South Asia & Pacific Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 164: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 165: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 166: South Asia & Pacific Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 167: South Asia & Pacific Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 168: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 169: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 170: South Asia & Pacific Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 171: South Asia & Pacific Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 172: South Asia & Pacific Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 173: South Asia & Pacific Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 174: South Asia & Pacific Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 175: South Asia & Pacific Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 176: South Asia & Pacific Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 177: South Asia & Pacific Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 178: South Asia & Pacific Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 179: South Asia & Pacific Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 180: South Asia & Pacific Cardiometabolic Drugs Market Attractiveness by Country, 2022-2032
Figure 181: MEA Cardiometabolic Drugs Market Value (US$ Mn) by Drug Class, 2022-2032
Figure 182: MEA Cardiometabolic Drugs Market Value (US$ Mn) by Route of Administration, 2022-2032
Figure 183: MEA Cardiometabolic Drugs Market Value (US$ Mn) by Indication, 2022-2032
Figure 184: MEA Cardiometabolic Drugs Market Value (US$ Mn) by Distribution Channel, 2022-2032
Figure 185: MEA Cardiometabolic Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 186: MEA Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 187: MEA Cardiometabolic Drugs Market (Tons) Analysis by Country, 2017-2032
Figure 188: MEA Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 189: MEA Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 190: MEA Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032
Figure 191: MEA Cardiometabolic Drugs Market (Tons) Analysis by Drug Class, 2017-2032
Figure 192: MEA Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032
Figure 193: MEA Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032
Figure 194: MEA Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Route of Administration, 2017-2032
Figure 195: MEA Cardiometabolic Drugs Market (Tons) Analysis by Route of Administration, 2017-2032
Figure 196: MEA Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Route of Administration, 2022-2032
Figure 197: MEA Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Route of Administration, 2022-2032
Figure 198: MEA Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Indication, 2017-2032
Figure 199: MEA Cardiometabolic Drugs Market (Tons) Analysis by Indication, 2017-2032
Figure 200: MEA Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Indication, 2022-2032
Figure 201: MEA Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Indication, 2022-2032
Figure 202: MEA Cardiometabolic Drugs Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
Figure 203: MEA Cardiometabolic Drugs Market (Tons) Analysis by Distribution Channel, 2017-2032
Figure 204: MEA Cardiometabolic Drugs Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
Figure 205: MEA Cardiometabolic Drugs Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
Figure 206: MEA Cardiometabolic Drugs Market Attractiveness by Drug Class, 2022-2032
Figure 207: MEA Cardiometabolic Drugs Market Attractiveness by Route of Administration, 2022-2032
Figure 208: MEA Cardiometabolic Drugs Market Attractiveness by Indication, 2022-2032
Figure 209: MEA Cardiometabolic Drugs Market Attractiveness by Distribution Channel, 2022-2032
Figure 210: MEA Cardiometabolic Drugs Market Attractiveness by Country, 2022-2032
FMI projects the sales of cardiometabolic drugs in the market is expected to rise at 4% to 5% value CAGR by 2032
The global cardiometabolic drugs market is expected to be dominated by North America over the forecast period 2022 to 2032.
AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others are some of the leading players in the key cardiometabolic drugs market.
Explore Similar Insights
Cardiometabolic Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
